MEF2C and acute myeloid leukemia: Moreover, KMT2A rearrangement and RUNX1-RUNX1T1 gene fusion are associated with high expression level of the lineage TF myocyte enhancer factor (MEF2C), which is a marker of poor prognostics in AML patients (Supplemental Fig. S1F) and controls AML cell proliferation31,32.